New hybrid approach intensifies treatment for liver tumor metastases
Combining intraarterial and intravenous administration of peptide receptor radionuclide therapy (PRRT) can selectively intensify treatment for liver-dominant metastatic neuroendocrine tumors (NETs) while still effectively delivering treatment throughout the whole body.
Read original article on The Medical News →Related news
-
Commerce Department under pressure for delaying export controls on Nvidia chips
United States
-
Couple with Autism and ADHD Find Passion Cleaning Filthy Street Signs
United Kingdom
-
ADHD's effects on breathing, perception and behavior
United Kingdom
-
Using AI to accelerate neuroscience research
United Kingdom
-
New biomarkers for Alzheimer's disease, depression and beyond
United Kingdom
-
Sex differences in pain, inflammation and Alzheimer's disease
United Kingdom
-
Brain-computer interfaces: A new voice for people with paralysis
United Kingdom
-
New brain-body connections expand understanding of Alzheimer's disease
United Kingdom